Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Nabriva Therapeutics plc (NASDAQ: NBRV) announced that CEO Ted Schroeder will present a company overview at the H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 am ET. This presentation will be available on-demand through the company’s website. Investor meetings are scheduled from May 24-26, 2022. Nabriva is focused on developing innovative anti-infective agents and has received FDA approval for XENLETA and is developing CONTEPO for serious infections.
- None.
- None.
DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference. The presentation will be available on-demand beginning on Tuesday, May 24 at 7:00 am ET. Management will also host investor meetings May 24-26, 2022.
The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com. A replay of the webcast will be available for 90 days.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
CONTACT:
For Investors and Media
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com
FAQ
When will Nabriva Therapeutics present at the H.C. Wainwright Global Investment Conference?
How can I access Nabriva Therapeutics' presentation from the conference?
What investor meetings are scheduled for Nabriva Therapeutics in May 2022?
What is Nabriva Therapeutics known for?
What products does Nabriva Therapeutics have FDA approval for?
